Singapore-based Tessa Therapeutics has shared clinical data from the pilot stage of an ongoing Phase 2 study of TT11, an autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy.
The data found that the CAR-T therapy had a favorable safety profile and promising efficacy in relapsed or refractory CD30-positive classical Hodgkin lymphoma (cHL) patients.
Recipients of the CAR-T therapy had a complete response (CR) rate of 57.1% and an overall response rate (ORR) of 71.4%.
The company shared the data in a presentation at the Annual Meeting of the American Society of Hematology (ASH).
Tessa announced that the TT11 CD30 CAR-T cells persisted for more than 42 days after infusion.
“These data demonstrate the promise of CD30-CAR-T cell therapy for patients with relapsed or refractory classical Hodgkin lymphoma who have limited treatment alternatives,” said Dr. Sairah Ahmed, principal investigator in a press release
Tessa notes that researchers have validated CD30 as a lymphoma target as it has homogenous expression in Classical Hodgkin Lymphoma and multiple subsets of non-Hodgkin lymphomas.